Someone seeking help might follow guidance that contradicts their clinician's care.
Most substance use reduction apps lack evidence-based approaches and make unsubstantiated claims, with app stores prioritizing revenue-generating products over scientifically validated options. Generative AI has accelerated marketplace flooding with untested products, creating safety gaps including inaccurate health information and failure to handle crisis situations appropriately.
- Most substance use reduction apps lack evidence-based approaches and make unsubstantiated claims
- Generative AI has accelerated marketplace flooding with untested products
- Current regulatory enforcement is nearly nonexistent
- Researchers propose FDA approval requirements and enforcement mechanisms like product removal
Experts warn that unregulated mobile health and AI apps claiming to help with substance use reduction lack scientific backing and oversight, leaving vulnerable populations exposed to misinformation that could hinder recovery.
Your phone buzzes with a notification for an app promising to help you cut back on drinking. The interface looks professional. The testimonials sound genuine. The language is peppered with scientific terms. You download it, start using it, and feel like you're finally taking control. What you don't know is that no one has tested whether this app actually works, that it may contain advice contradicting established treatment protocols, and that the company behind it prioritizes ad revenue over your recovery.
This scenario plays out thousands of times daily across app marketplaces, according to researchers at Rutgers Health, Harvard University, and the University of Pittsburgh who published their concerns in the Journal of the American Medical Association. Jon-Patrick Allem, an associate professor at Rutgers School of Public Health and senior author of the commentary, points to a fundamental market failure: app stores promote products that generate advertising income rather than those backed by rigorous science. The result is a landscape where evidence-based applications become harder to find, buried beneath flashy competitors making bold claims about effectiveness.
The problem runs deeper than simple marketing. Systematic reviews consistently show that most substance use reduction apps fail to employ proven, evidence-based methods. Instead, they rely on scientific-sounding language and exaggerated promises to appear credible. While controlled studies demonstrate that some mobile health apps can genuinely help people reduce alcohol consumption and other substance use, their real-world impact remains limited. The gap between what works in a research setting and what actually helps people in their daily lives is substantial, yet consumers have little way to distinguish between legitimate tools and sophisticated marketing.
Generative artificial intelligence has accelerated this problem dramatically. The rapid development and deployment capabilities of AI tools have flooded marketplaces with untested, unregulated products almost faster than they can be catalogued. While general-purpose AI models like ChatGPT have shown promise in providing accurate health information, significant safety gaps persist. These range from delivering inaccurate medical guidance to failing to respond appropriately when users are in crisis, to inadvertently normalizing unsafe behaviors. For someone struggling with substance use disorder, these lapses can be catastrophic.
Currently, enforcement is nearly nonexistent. The regulatory vacuum leaves vulnerable populations exposed to misinformation that can actively hinder treatment and recovery. Someone seeking help might spend weeks following guidance from an app that contradicts what their clinician recommends, or worse, that encourages them to avoid professional care altogether. The stakes are not abstract: they involve people's health, their families, their chances at recovery.
Consumers can protect themselves by learning what to look for. Evidence-based apps typically cite peer-reviewed research, were developed in collaboration with universities or licensed professionals, have been independently evaluated and published in scientific journals, clearly explain data storage and privacy compliance, and avoid guaranteeing results. Red flags include vague claims like "clinically proven" without specifics, methods that seem too simple or too good to be true, and lack of transparency about who built the app and how it was tested.
Allem and his colleagues propose stronger oversight mechanisms. One approach gaining traction is requiring Food and Drug Administration approval, which would mandate that apps undergo randomized clinical trials and meet defined standards before reaching consumers. Until such requirements exist, clear labeling becomes essential—people need to know which apps have evidence behind them and which do not. Enforcement mechanisms matter too: fines, suspensions, and removal of noncompliant products from app stores could create real consequences for misleading claims.
The conversation is urgent because the marketplace continues expanding. Every day, new apps launch claiming to help with substance use reduction. Some will help. Many will not. Without intervention, the landscape will only grow more crowded and more confusing, making it harder for people who genuinely want to recover to find tools that actually work.
Citas Notables
Greater transparency and stricter regulation could safeguard people from being misled by information portrayed as verifiable public health information.— Jon-Patrick Allem, Rutgers Institute for Nicotine and Tobacco Studies
The massive lack of enforcement leaves huge populations vulnerable to misinformation, which can hinder treatment and chances of recovery for individuals with substance use disorder.— Rutgers Health, Harvard University, and University of Pittsburgh researchers
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that app stores prioritize revenue over science? Couldn't someone just read reviews and figure out which apps are legitimate?
Reviews are often written by people in the early stages of using an app, before they'd know if it actually works. And companies can game review systems. The real problem is that someone struggling with addiction is in a vulnerable state—they're looking for help, and they're not in a position to conduct a literature review.
You mentioned that some apps do work in controlled studies but not in real life. What's the difference?
In a study, people are monitored, reminded to use the app, supported by researchers. In real life, you're alone with your phone, and if the app isn't genuinely useful, you'll stop using it. But by then you might have delayed seeking actual treatment.
What's the specific danger with generative AI apps versus traditional apps?
Speed. A traditional app takes months or years to build and test. An AI tool can generate a fully functional app in days. That means the marketplace is flooded with untested products before anyone can evaluate them. And AI can sound authoritative while being completely wrong.
If someone is using one of these apps right now, what should they do?
Check who built it. If it's a company you've never heard of with no affiliation to a university or hospital, be skeptical. Look for published research about the app itself, not just general claims about the approach. And talk to a clinician—don't let an app replace professional guidance.
Why hasn't the FDA already stepped in?
FDA approval takes time and resources. The app marketplace moves faster than regulation can. There's also been a philosophy that health apps are just tools, not drugs, so they don't need the same oversight. That's changing, but slowly.
What would FDA approval actually mean for someone using these apps?
It would mean someone with substance use disorder could trust that an app on the shelf has actually been tested to work, that its claims are backed by evidence, and that it won't give dangerous advice. Right now, that trust doesn't exist.